Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | PTPRF | P10586 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863175 | 0.85 | CA12 (0.50) | PTPN1MAPTRAB9AALDH1A1CA1 | |
| SCHEMBL28787158 | 0.84 | EGFR (0.52) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL7176319 | 0.83 | EGFR (0.55) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL3311897 | 0.82 | EGFR (0.50) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL6539223 | 0.82 | EGFR (0.50) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL28270387 | 0.81 | EGFR (0.52) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL30307414 | 0.80 | HTT (0.49) | EGFRSLC6A3MAPTALDH1A1CA1 | |
| SCHEMBL27708108 | 0.80 | EGFR (0.71) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL13232062 | 0.78 | EGFR (0.64) | PTPN1PTPRCPTPRFCDC25BEGFR | |
| SCHEMBL1772614 | 0.78 | TSHR (0.50) | TSHRMAPTRAB9AALDH1A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| WO-2015141958-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 현대약품 주식회사 | 2015-09-24 | — | — | WO | disclosed |
| CN-1537105-A | Quinazolines useful as MMP-13 inhibitors | ��������ʲ��������ι�˾ | 2004-10-13 | — | — | CN | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-5332744-A | Hypotensive, congestive heart failure, intraocular pressure | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| US-5157026-A | Oxo-purines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5102880-A | Biphenyl imidazotriazine derivatives; Hypotensive and cardiotonic agents | MERCK & CO., INC. (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | PTPN1 345/4885PTPRC 1944/4885PTPRF 2448/4885 |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | PPARG, CDK5, CDK5R1 | PTPN1 2337/4885PTPRC 2029/4885PTPRF 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.